News | Cath Lab | March 04, 2016

GlobalData: Stenting Viable Alternative to Surgery in Carotid Artery Stenosis

Opposing procedures show similar rates of adverse events and restenosis in CREST trial

CREST trial results, New England Journal of Medicine, stenting, endarterectomy, carotid artery stenosis

March 4, 2016 — Recent results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) are evidence that stenting will continue to remain competitive with surgical treatment, said an analyst with research and consulting firm GlobalData. CREST data has shown patients with severe carotid artery stenosis suffered similar rates of adverse events in both stenting and endarterectomy procedures.

The 10-year findings of the trial, published by the New England Journal of Medicine, showed adverse event rates of 11.8 percent in stenting and 9.9 percent in endarterectomy groups, with no significant difference in restenosis rates. In this way, both procedures exhibit similar long-term, post-procedural safety and efficacy profiles.

Premdharan Meyyan, GlobalData's analyst covering medical devices, states that in order for stenting to experience increased uptake, developers should prioritize improving solutions for embolic protection to minimize periprocedural stroke risk.

Meyyan said: “Carotid stenting systems with flow reversal and integrated embolic protection have potential to address the challenges with the current generation of products. GlobalData expects there will be an increased demand for these systems in coming years.

“Indeed, major peripheral vascular players that have developed and launched proximal embolic protection systems that incorporate flow reversal or arrest, with high rates of technical success, include Medtronic with its MoMa Ultra, and W.L Gore with its Gore Flow Reversal System.”

The analyst added that mesh-covered stents are also emerging as a potential solution to the periprocedural stroke rate. InspireMD has developed the CE-marked CGuard nitinol stent, which utilizes a polyethylene terephthalate mesh to provide continuous embolic protection, showing 100 percent procedural success and no major adverse events at the 30-day mark. 

Meyyan concluded: “These new technologies are promising, and show that opportunities continue to be available for companies to devise carotid artery stenting systems.

“Despite stenting’s stable reputation following the CREST trial results, the outcome from the CREST-2 trial, which compares clinical outcomes of surgery, stenting and medical therapy, will be pivotal in determining the future direction of carotid artery disease management.”

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init